MLCARE Machine Learning Computational Advancements for peRsonalized mEdicine
- Coordinator
- Universidad Carlos Iii De Madrid, Spain
- Runs
- 1 January 2026 to 31 December 2029
- Status
- Running
- EU funding
- €3.9m
- Total cost
- —
- Partners
- 24 organisations in 10 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101226456
What the project is doing
In the project's own words, from its summary on CORDIS.
Personalized medicine represents a paradigm shift in healthcare, transitioning from generalized treatment strategies to highly personalized care. This transformation is driven by rapid advancements in digital technologies, which generate massive volumes of data from diverse sources, including genomic sequences, high-resolution imaging, wearable devices, and electronic health records (EHRs). However, despite an annual estimate of 50 petabytes of data generated per hospital, only a fraction is utilized effectively.
Harnessing this untapped potential offers a transformative opportunity to uncover novel disease mechanisms and deliver more precise and effective therapeutic interventions. The MLCARE project seeks to revolutionize personalized medicine by developing cutting-edge AI solutions that integrate genomic, clinical, and environmental data into holistic, multimodal patient representations. Through innovative approaches such as Foundation Models and advanced generative AI methods, MLCARE will address critical challenges in processing complex, high-dimensional, and multimodal datasets.
Emphasis will be placed on ensuring the trustworthiness, explainability, and security of AI applications to support real-world clinical decision-making. A core mission of MLCARE is to train a new generation of interdisciplinary researchers with expertise spanning AI, computational biology, and healthcare. The program will equip doctoral candidates with the technical, analytical, and ethical skills needed to lead the future of patient-centered, AI-driven medicine.
By combining state-of-the-art research with a comprehensive training program, MLCARE aims to set new standards in personalized healthcare, ensuring equitable, data-driven solutions that improve outcomes across diverse populations. This project is poised to position Europe at the forefront of global innovation in precision medicine, delivering a timely and impactful response to evolving healthcare challenges.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidad Carlos Iii De Madrid | Getafe (Madrid) | Spain | Coordinator |
| Universite De Liege | Liege | Belgium | Participant |
| Eidgenoessische Technische Hochschule Zuerich | Zuerich | Switzerland | Associatedpartner |
| Hmnc Holding GmbH | Munchen | Germany | Participant |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eV | Munchen | Germany | Participant |
| Siemens Healthineers AG | Forchheim | Germany | Associatedpartner |
| Kobenhavns Universitet | Kobenhavn | Denmark | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Associatedpartner |
| Tartu Ulikool | Tartu | Estonia | Participant |
| Astrazeneca Farmaceutica Spain, S.a | Madrid | Spain | Associatedpartner |
| Evidence-Based Behavior, SL | Leganes | Spain | Associatedpartner |
| Fundacio Barcelonabeta Brain Research Center | Barcelona | Spain | Participant |
| Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon | Madrid | Spain | Associatedpartner |
| Fundacion Publica Andaluza Progreso Y Salud M.p. | Sevilla | Spain | Participant |
| Universidad De Sevilla | Sevilla | Spain | Associatedpartner |
| Universidad Pompeu Fabra | Barcelona | Spain | Associatedpartner |
| Institut Pasteur | Paris | France | Associatedpartner |
| Universite Paris Cite | Paris | France | Participant |
| Universiteit Maastricht | Maastricht | Netherlands | Associatedpartner |
| Pixelgen Technologies AB | Stockholm | Sweden | Associatedpartner |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Participant |
| Pharmatics Limited | Edinburgh | United Kingdom | Participant |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI